



Research Article

An *in vitro* Study: Inhibitory Effect of Carfilzomib on Human Serum Paraoxonase-1 (hPON1)

Hakan Soyut

Department of Primary Education, Faculty of Education, Bursa Uludağ University, Bursa, Turkey

Abstract

Background and Objective: hPON1 is an HDL-related lactonase that can inhibit LDL. It is considered atheroprotective. hPON1 contributes to the antioxidant function of HDL. It is believed that a decrease in PON1 activity may promote atherosclerosis. This article was aimed to investigate the inhibitory effect of carfilzomib on hPON1. **Materials and Methods:** In this study, we detect the inhibition between hPON1 and carfilzomib used in the treatment of myeloma. **Results:** We determined that carfilzomib showed very strong inhibitory properties for human serum PON1, with an IC_{50} value of 43.31 μ M and a mean K_i value of 44.37 μ M. We determined that carfilzomib showed competitive inhibition. **Conclusion:** The use of carfilzomib, which has a very strong inhibitory effect, in the treatment of multiple myeloma can be very harmful.

Key words: Paraoxonase, carfilzomib, inhibition, anticancer drug, multiple myeloma, HDL, lymphoblastic lymphoma

Citation: Soyut, H., 2022. An *in vitro* study: Inhibitory effect of carfilzomib on human serum paraoxonase-1 (hPON1). *Int. J. Pharmacol.*, 18: XX-XX.

Corresponding Author: Hakan Soyut, Department of Primary Education, Education Faculty, Bursa Uludağ University, Bursa, Turkey
Tel: +902242940000-40954/+905537411369

Copyright: © 2021 Hakan Soyut. This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

Multiple Myeloma (MM) is a clonal plasma cell malignancy that accounts for approximately 13% of haematological cancers¹. Multiple myeloma results from the oncogenic transformation of the white blood cells responsible for producing antibodies². Multiple myeloma cells accumulate in the bone marrow, where the production of blood cells occurs³. The progression of multiple myeloma is assessed by measuring the amount of M protein in the serum⁴. Carfilzomib was approved in 2012 by the US Food and Drug Administration as a proteasome inhibitor for the treatment of multiple myeloma⁵. Paraoxonase (hPON1) activity was lower in multiple myeloma patient serum⁶. In addition, decreased activity of hPON1 has been suggested as a poor prognostic marker of multiple myeloma patients⁷. Human serum paraoxonase-1 (EC 3.1.8.1, hPON1) is a Ca²⁺ dependent lactonase associated with High-Density Lipoprotein (HDL)⁸. hPON1 is synthesized in the liver and is secreted into the blood. It is a glycoprotein with a molecular weight of 43-45 kDa. hPON1 has been detected in a wide variety of mammalian tissues, including human serum, by biochemical studies. However, it is not found in the blood of birds, fish and most reptiles⁹. hPON1 is also associated with HDL that contains Apo A1 and clusterin. In ultracentrifugation, the majority of hPON1 is found in HDL¹⁰.

hPON1 is the first discovered member of the multiple gene families, including PON1, PON2 and PON3. Three-member genes of the family are widely expressed in mammalian tissues¹¹. hPON1 is mostly found in HDL-associated plasma, while PON2 and PON3 are not found in plasma¹². hPON1 delays Low-Density Lipoprotein (LDL) oxidative modification and is therefore admitted antiatherogenic¹³. In addition, hPON1 is accepted to be an important factor in the antioxidant activity of HDL as it contributes to the antioxidant effect of HDL¹⁴.

In the serum of patients affected by different types of cancer, such as lung cancer, gastrointestinal cancer, breast and gynaecological cancer, prostate, bladder cancer, central nervous system tumours, non-Hodgkin lymphoma and Acute Lymphoblastic Lymphoma (ALL), hPON1 activity is significantly lower. A decrease in hPON1 activity may negatively affect the antioxidant role of the enzyme and expose it to higher oxidative stress¹⁵.

The effect of anti-cancer drugs on hPON1 has not been extensively studied. Rats treated with cyclophosphamide, a chemotherapeutic drug, showed a 2 fold increase in renal hPON1 activity. In contrast, a reduced hPON1 activity was observed *in vitro* during incubations with chemotherapeutic

agents (cetuximab, paclitaxel, etoposide, docetaxel and ifosfamide) when purified hPON1 was used¹⁶. Oxidative stress and inflammation are considered important factors that play a role in the development of cancer and in determining the prognosis of chemotherapy. There is an inverse proportion between hPON1 enzyme activity and oxidative stress in cancer patients. If any drug reduces PON1 enzyme activity, it can occur many vascular diseases, including atherosclerosis, due to increased oxidative stress¹⁷.

In this study, we investigated the *in vitro* inhibition effect of carfilzomib, which is widely used in cancer treatment, on hPON1 enzyme activity.

MATERIALS AND METHODS

Study area: The study was carried out at the Department of Chemistry, Research Lab, Turkey from April-July, 2021.

Chemicals: All chemicals were obtained from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Carfilzomib was obtained from Bursa Uludağ University Faculty of Medicine Oncology Department.

Paraoxonase activity measurement: Human serum samples were obtained from Erzincan Mengücekgazi Research Hospital. Paraoxonase activity of the enzyme was determined by using paraoxon as substrate in a 50 mM glycine/NaOH (pH: 10.5) buffer solution containing 1 mM CaCl₂ at 25°C. The activity measurement is based on the absorption at 412 nm of paranitrophenol formed as a result of the reaction of paraoxon and PON1 enzyme. The enzyme unit of paraoxonase is the number of micromoles of paraoxon hydrolyzed in 1 min¹⁸. Activity measurement was performed using a spectrophotometer (Chebios UV-VIS).

Determination of IC₅₀ and K_i constants for chemotherapeutic drug: The inhibitory effect of carfilzomib, which is widely used in cancer chemotherapy, was investigated. This chemotherapeutic drug was tested 3 times for each concentration. Paraoxonase activities of the enzyme were analyzed at different drug concentrations. Graphs were plotted showing percent activity for carfilzomib as a function of drug concentration. Control activity in the absence of inhibitor was accepted as 100%. The 50% inhibition (IC₅₀ value) of carfilzomib was obtained from the graphs using different inhibitor concentration values. To calculate K_i values, 3 different inhibitory concentrations of carfilzomib were tested. Lineweaver-Burk curves were used to determine the values of K_i and the type of inhibition.




Fig. 1: Activity (%) concentration graph used to determine the IC_{50} value




Fig. 2: Lineweaver-Burk graph used to determine K_i constant

RESULTS

In this study, the *in vitro* inhibition effect of carfilzomib on paraoxonase enzyme activity was studied. For carfilzomib, which inhibits hPON1- IC_{50} value (inhibitor concentration that halves the enzyme's activity) was determined by plotting (%) activity-[Carfilzomib] graphs using 5 different inhibitor concentrations at constant paraoxon concentration. The IC_{50} value was calculated as 43.31 μM from the curve equation in the graph (Fig. 1).

Then, $1/V-1/\text{paraoxon}$ values were found by using the activity values obtained at 3 different inhibitor (I1:20, I2:40 and I3:60 μM) concentrations and 5 different paraoxon (1.33, 1.66, 2.22, 3.33 and 6.66 μM^{-1}) concentrations for carfilzomib. K_i values were calculated by drawing lineweaver-burk graphs. The average K_i value was found to be 44.37 μM (Fig. 2). The type of inhibition is competitive.

DISCUSSION

In this study, the inhibition effect of carfilzomib, an anti-cancer drug, on paraoxonase activity was performed. The IC_{50} value for carfilzomib was determined as 43.31 μM using the Activity-[1] (%) graph (Fig. 1). In our study, Lineweaver-Burk graphs were used to determine the K_i constant for carfilzomib, which has an inhibitory effect on the human serum hPON1 enzyme. The K_i constant was determined as 44.37 μM (Fig. 2). The type of inhibition is competitive. Reducing the paraoxonase activity of drugs can lead to critical consequences such as cardiovascular diseases. hPON1 is one of the antioxidant defense mechanisms in the human body. There are many scavenging systems for reactive oxygen species in the human body. hPON1 protects LDL, HDL and macrophages against oxidative stress by scavenging reactive oxygen species in living metabolism. Therefore, hPON1 prevents cardiovascular diseases¹⁹. hPON1 is a calcium-dependent esterase that hydrolyzes compounds such as organophosphate tryters, aryl esters, cyclic carbamates, glucuronides, estrogen esters and thiolactones. However, the physiological substrate of hPON1 is lactones²⁰.

There are many studies on the interactions between hPON1 activity and drugs. Statins are a group of lactone substrates. They act by reducing LDL. Decreased LDL causes an increase in hPON1 activity. Increasing hPON1 activity contributes to the reduction of oxidative stress and the prevention of cardiovascular diseases. Pravastatin, simvastatin and atorvastatin have a positive effect on hPON1 activity²¹⁻²³. Aspirin is widely used in the treatment and prevention of vascular diseases. It was tested that aspirin may have beneficial effects on hPON1 activity. Aspirin use significantly increased hPON1 activity in patients with coronary artery disease²⁴. Valsartan and barnidipine were found to not affect hPON1 activity^{25,26}. In another study, gentamicin sulfate and cefazolin sodium decreased hPON1 activity²⁷.

Various enzyme-anticancer drug interaction studies have been carried out in our laboratory. For example, Trke *et al.*²⁸ examined the *in vitro* effects of some anti-cancer drugs, (1) Palonosetron hydrochloride, (2) Bevacizumab and (3) Cyclophosphamide on hPON1. Anti-cancer drugs must be potent inhibitors of human serum hPON1. Compared with other anti-cancer drugs, palonosetron hydrochloride was found to inhibit enzyme activity significantly. The inhibition order of drugs was determined as 1>2>3. As stated above, carfilzomib strongly inhibited the enzyme in this study. Cardiovascular disorders may occur in cancer patients using this drug, as the activity of the PON1 enzyme will decrease. However, this study can be illuminated by oncological studies.

CONCLUSION

In conclusion, we investigated the *in vitro* effects of carfilzomib on hPON1. We did not encounter any literature on the relationship between hPON1 and carfilzomib. However, it is known that the expression and activity of the paraoxonase enzyme are critical for cancer diseases. Many studies have shown a decrease in hPON1 activities in different cancer patients. hPON1 is a multifunctional enzyme involved in the regulation of antioxidant defence and cell behaviour. In addition, hPON1 activity protects against cardiovascular diseases. Carfilzomib is used as a chemotherapeutic drug in the treatment of cancer. When applied in cancer therapy, they may cause some metabolic disorders, especially in patients with atherosclerotic lesions. However, our results should be confirmed by some *in vivo* studies.

SIGNIFICANCE STATEMENT

This study discovered the inhibitory effect of carfilzomib on hPON1, which many researchers failed to discover, which may be useful for understanding the adverse effects of carfilzomib on cardiovascular diseases. Thus, a new theory may have been reached regarding the use of carfilzomib in cancer treatment.

REFERENCES

1. Siegel, R.L., K.D. Miller and A. Jemal, 2016. Cancer statistics, 2016. CA: Cancer J. Clinicians, 66: 7-30.
2. Hideshima, T. and K.C. Anderson, 2002. Molecular mechanism of novel therapeutic approaches for Multiple myeloma. Nat. Res. Cancer, 2: 927-937.
3. Röllig, C., S. Knop and M. Bornhäuser, 2015. Multiple myeloma. Lancet, 385: 2197-2208.
4. Rajkumar, S.V., O. Landgren and M.V. Mateos, 2015. Smoldering multiple myeloma. Blood, 125: 3069-3075.
5. Kortuem, K.M. and A.K. Stewart, 2013. Carfilzomib. Blood, 121: 893-897.
6. Faridvand, Y., A.E. Oskuyi and M.H. Khadem-Ansari, 2016. Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma. Redox Rep. Commun. Free Radical Res., 5: 204-208.
7. Ellidag, H.Y., E. Eren, O. Aydin, M. Yildirim, C. Sezer and N. Yilmaz, 2014. Multiple myeloma: Relationship to antioxidant esterases. Med. Principles Pract., 23: 18-23.
8. Rajkovic, M.G., L. Rumora and K. Barisic, 2011. The paraoxonase 1, 2 and 3 in humans. Biochemia Med., 2: 122-130.
9. Marsillach, J., B. Mackness, M. Mackness, F. Riu, R. Beltrán, J. Joven and J. Camps, 2008. Immunohistochemical analysis of paraoxonases-1, 2 and 3 expression in normal mouse tissues. Free Radical Biol. Med., 45: 146-157.
10. Davidson, W.S., R.A.G.D. Silva, S. Chantepie, W.R. Lagor, M.J. Chapman and A. Kontush, 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arteriosclerosis Thrombosis Vasc. Biol., 29: 870-876.
11. Rodríguez-Sanabria, F., A. Rull, R. Beltrán-Debón, G. Aragonès and J. Camps *et al*, 2010. Tissue distribution and expression of paraoxonases and chemokines in mouse: The ubiquitous and joint localisation suggest a systemic and coordinated role. J. Mol. Histol., 41: 379-386.
12. Aviram, M. and M. Rosenblat, 2004. Paraoxonases 1, 2 and 3, oxidative stress and macrophage foam cell formation during atherosclerosis development. Free Radical Biol. Med., 37: 1304-1316.
13. Reddy, S.T., A. Devarajan, N. Bourquard, D. Shih and A.M. Fogelman, 2008. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr. Opin. Lipidology, 19: 405-408.
14. Deakin, S.P., S. Bioletto, M.L. Bochaton-Piallat and R.W. James, 2011. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radical Biol. Med., 50: 102-109.
15. Barrera, G., 2012. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol., Vol. 2012. 10.5402/2012/137289.
16. Ferretti, G., T. Bacchetti and A. Sahebkar, 2015. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res., 60: 50-73.
17. Alim, Z. and Ş. Beydemir, 2016. Some anticancer agents act on human serum paraoxonase-1 to reduce its activity. Chem. Biol. Drug Des., 88: 188-196.
18. Renault, F., E. Chabriere, J.P. Andrieu, B. Dublet, P. Massona and D. Rochua, 2006. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography. J. Chromatogr. B, 836: 15-21.
19. Golmanesh, L., H. Mehrani and M. Tabei, 2008. Simple procedures for purification and stabilization of human serum paraoxonase-1. J. Biochem. Biophys. Methods, 70: 1037-1042.
20. Draganov, D.I., J.F. Teiber, A. Speelman, Y. Osawa, R. Sunahara and B.N.L. Du, 2005. Human paraoxonases (PON1, PON2 and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res., 46: 1239-1247.
21. Kumar, A., 2010. Effect of simvastatin on paraoxonase 1 (PON1) activity and oxidative stress. Asian Pac. J. Trop. Med., 3: 310-314.

22. Malin, R., R. Laaksonen, J. Knuuti, T. Janatuinen, R. Vesalainen, P. Nuutila and T. Lehtimäki, 2001. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. *Pharmacogenetics*, 11: 625-633.
23. Nagila, A., T. Permpongpaiboon, S. Tantramongroj, P. Porapakham, K. Chinwattana, S. Deakin and S. Porntadavity, 2009. Effect of atorvastatin on paraoxonase 1 (PON1) and oxidative status. *Pharmacol. Rep.*, 61: 892-898.
24. Bhattacharyya, T., S.J. Nicholls, E.J. Topol, R. Zhang and X. Yang *et al.*, 2008. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. *J. Am. Med. Assoc.*, 299: 1265-1276.
25. Saisho, Y., N. Komiya and H. Hirose, 2006. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. *Diab. Res. Clin. Pract.*, 74: 201-203.
26. Spirou, A., E. Rizos, E.N. Liberopoulos, N. Kolaitis, A. Achimastos, A.D. Tselepis and M. Elisaf, 2006. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: A pilot study. *J. Cardiovasc. Pharmacol. Ther.*, 11: 256-261.
27. Sinan, S., F. Kockar, N. Gencer, H. Yildirim and O. Arslan, 2006. Effects of some antibiotics on paraoxonase from human serum *in vitro* and from mouse serum and liver *in vivo*. *Biol. Pharm. Bull.*, 29: 1559-1563.
28. Türkeş, C., H. Söyüt and Ş. Beydemir, 2016. *In vitro* inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum. *Environ. Toxicol. Pharmacol.*, 42: 252-257.